The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

3d illustration of Man suffering migraine
Valuing Drugs For Acute Migraine

The Institute for Clinical and Economic Review revised its cost effectiveness estimates for Allergan PLC’s new oral CGRP receptor antagonist for acute treatment of migraine after the company re-analyzed data demonstrating the drug's effectiveness when some patients had to wait beyond two hours to feel the benefit.

The revisions were discussed at a meeting of ICER’s Midwestern Comparative Effectiveness Public Advisory Council on 23 January.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip